Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INE963 in uncomplicated Plasmodium falciparum malaria
NCT07235020Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of INE963 in Plasmodium falciparum malaria, sponsored by Novartis. Started Jan 2024; status: completed.
02
Drugs
INE963
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT07235020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235020.